$KRTL KRTL Holding Appoints Dave Orn and Rick Haxton to Accelerate Global Growth at KRTL Biotech Inc.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=481976
KRTL Holding Group Inc. (OTC: KRTL) today announced the appointment of David Orn as Chief Revenue Officer (CRO) and Rick Haxton as Global Sales Director of its wholly owned subsidiary, KRTL Biotech Inc. These leadership appointments represent a strategic step forward in enhancing KRTL Biotech's revenue generation capabilities and expanding its global market presence.
David Orn, previously an Independent Director of KRTL Holding's Board, transitions into an executive leadership role, bringing decades of experience in healthcare, technology, and strategic development. In his new role as CRO, David will oversee all revenue-generating departments, including sales, business development, and strategic partnerships.
Rick Haxton, newly appointed Global Sales Director, offers extensive expertise in building and leading global sales organizations. His career includes successful track records in domestic and international markets with a focus on regulatory compliance and commercial execution.
"We are extremely pleased to have David and Rick, long-time business partners with a shared history of successful collaboration, bring their combined relationships and complementary expertise to KRTL Biotech. Their established synergy and proven track record position them uniquely to drive the Company's revenue growth and market expansion," said Cesar Herrera, CEO of KRTL Holding Group. "Their leadership experience, industry knowledge, and deep business connections position us to significantly accelerate our revenue growth initiatives and expand market reach. This is a powerful alignment for the future of KRTL Biotech."
As part of their mandate, David and Rick will lead commercialization strategies for KRTL Biotech's pharmaceutical and nutraceutical products, leveraging their networks to build strategic partnerships and drive operational excellence.
"I'm excited to take on this new role and collaborate with Rick to realize the tremendous potential at KRTL Biotech," said David Orn. "Together, we aim to drive sustainable growth and deliver innovative solutions to the market."
"This is an exciting time to join KRTL Biotech," said Rick Haxton. "We are well-positioned to expand our footprint and execute a robust go-to-market strategy that enhances shareholder value."
KRTL Biotech's enhanced leadership team demonstrates the Company's commitment to innovation, strategic execution, and long-term value creation.
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=481976
KRTL Holding Group Inc. (OTC: KRTL) today announced the appointment of David Orn as Chief Revenue Officer (CRO) and Rick Haxton as Global Sales Director of its wholly owned subsidiary, KRTL Biotech Inc. These leadership appointments represent a strategic step forward in enhancing KRTL Biotech's revenue generation capabilities and expanding its global market presence.
David Orn, previously an Independent Director of KRTL Holding's Board, transitions into an executive leadership role, bringing decades of experience in healthcare, technology, and strategic development. In his new role as CRO, David will oversee all revenue-generating departments, including sales, business development, and strategic partnerships.
Rick Haxton, newly appointed Global Sales Director, offers extensive expertise in building and leading global sales organizations. His career includes successful track records in domestic and international markets with a focus on regulatory compliance and commercial execution.
"We are extremely pleased to have David and Rick, long-time business partners with a shared history of successful collaboration, bring their combined relationships and complementary expertise to KRTL Biotech. Their established synergy and proven track record position them uniquely to drive the Company's revenue growth and market expansion," said Cesar Herrera, CEO of KRTL Holding Group. "Their leadership experience, industry knowledge, and deep business connections position us to significantly accelerate our revenue growth initiatives and expand market reach. This is a powerful alignment for the future of KRTL Biotech."
As part of their mandate, David and Rick will lead commercialization strategies for KRTL Biotech's pharmaceutical and nutraceutical products, leveraging their networks to build strategic partnerships and drive operational excellence.
"I'm excited to take on this new role and collaborate with Rick to realize the tremendous potential at KRTL Biotech," said David Orn. "Together, we aim to drive sustainable growth and deliver innovative solutions to the market."
"This is an exciting time to join KRTL Biotech," said Rick Haxton. "We are well-positioned to expand our footprint and execute a robust go-to-market strategy that enhances shareholder value."
KRTL Biotech's enhanced leadership team demonstrates the Company's commitment to innovation, strategic execution, and long-term value creation.
